Pharmacological, Optical, and Combined Approaches to Myopia Control in Bulgarian Children: A Longitudinal Study
Open Access
- 1 June 2026
- journal article
- Published by Walter de Gruyter GmbH in Acta Medica Bulgarica
- Vol. 53 (2) , 10-15
Abstract
This study presents different treatments, including both medication and glasses, that affect the progression of myopia in children over time. A total of 250 children aged 6 to 16 were evaluated for a period of 36 months. For the purpose of the study, four groups were formed: one group of pediatric patients receiving low-dose atropine (0.01%), another group wearing defocus-modifying glasses, a third group receiving both treatments, and a control group with no treatment. Key biometric indicators, such as axial length, spherical equivalent, and best-corrected visual acuity, were measured at the start of the study and after that every six months. Non-parametric statistical methods were used to compare changes within each group over time and to identify differences between groups. The protocol achieved high data completeness and showed significant changes within the groups (p<0.001). Clear differences between groups appeared after 12 months. The results suggest that combining atropine and defocus lenses is most effective in slowing myopia progression while maintaining good vision.Keywords
This publication has 30 references indexed in Scilit:
- Prevalence of myopia in Europe: a systematic review and meta-analysis of data from 14 countriesThe Lancet Regional Health - Europe, 2025
- Complications of high myopia: An update from clinical manifestations to underlying mechanismsAdvances in Ophthalmology Practice and Research, 2024
- Increasing prevalence of myopia in patients undergoing retinal detachment repair: an 11-year service evaluationEye, 2023
- Urban Living Environment and Myopia in ChildrenJAMA Network Open, 2023
- Interventions for myopia control in children: a living systematic review and network meta-analysisCochrane Database of Systematic Reviews, 2023
- The Risks and Benefits of Myopia ControlOphthalmology, 2021
- Side effects of topical atropine 0.05% compared to 0.01% for myopia control in German school children: a pilot studyInternational Ophthalmology, 2021
- Low-Concentration Atropine for Myopia Progression (LAMP) StudyOphthalmology, 2019
- The epidemics of myopia: Aetiology and preventionProgress in Retinal and Eye Research, 2018
- Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)Ophthalmology, 2012